SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Pincus T, Wolfe F, Callahan LF. Updating a reassessment of traditional paradigms concerning rheumatoid arthritis. In: WolfeF, PincusT, editors. Rheumatoid arthritis: pathogenesis, assessment, outcome, and treatment. New York: Marcel Dekker; 1994. p. 174.
  • 2
    Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum 1998; 41: 157182.
  • 3
    Emery P. Rheumatoid arthritis: not yet curable with early intensive therapy. Lancet 1997; 350: 3045.
  • 4
    Harris ED Jr. The rationale for combination therapy in rheumatoid arthritis based on pathophysiology. J Rheumatol 1996; 23 (suppl 44): 8690.
  • 5
    Felson DT, Anderson JJ, Meenan RF. The efficacy and toxicity of combination therapy in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 1994; 37: 148791.
  • 6
    O'Gradaigh D, Scott DGI. Pyramids to myriads: the combination conundrum in rheumatoid arthritis. Clin Exp Rheumatol 1999; 18 (suppl 17): 139.
  • 7
    Choy E, Panayi G. Mechanisms of action of second-line agents and choice of drugs in combination therapy. Clin Exp Rheumatol 1999; 18 (suppl 17): 208.
  • 8
    Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995; 333: 13741.
  • 9
    Stein CM, Pincus T, Yocum D, Tugwell P, Wells G, Gluck O, et al. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. Arthritis Rheum 1997; 40: 184351.
  • 10
    Stein CM, Pincus T. Combination treatment of rheumatoid arthritis with cyclosporine and methotrexate. Clin Exp Rheumatol 1999; 18 (suppl 17): 4752.
  • 11
    Yocum D, Allard S, Laasonen L, Marubini E, Ferrara R, Della Casa-Alberighi O. Pooled 48-week efficacy and safety results of two double blind randomized controlled studies comparing MTX plus cyclosporine (CSA) versus MTX plus placebo (PI) in patients with early severe RA [abstract]. Arthritis Rheum 2000; 43 (suppl 9): S344
  • 12
    Proudman SM, Conaghan PG, Richardson C, Griffiths B, Green MJ, McGonagle RJ, et al. Treatment of poor-prognosis early rheumatoid arthritis: a randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000; 43: 180919.
  • 13
    Stucki G, Langenegger T. Management of rheumatoid arthritis. Curr Opin Rheumatol 1997; 9: 22935.
  • 14
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 15
    Ranza R, Marchesoni A, Calori G, Bianchi G, Braga M, Canazza S, et al. The Italian version of the Functional Disability Index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol 1993; 11: 1238.
  • 16
    Van Gestel AM, Haagsma CJ, van Riel PLCM. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 184550.
  • 17
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 72735.
  • 18
    Van Gestel AM, Prevoo MIL, van't Hof MA, van Rijswijck MH, van de Putte LBA, van Riel PLCM. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 3440.
  • 19
    Larsen A, Dale K, Eek M, Pahle J. Radiographic evaluation of rheumatoid arthritis by standard reference films. J Hand Surg 1983; 8: 66769.
  • 20
    Cronstein BN. Molecular therapeutics: Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39: 195160.
  • 21
    Segal R, Yaron M, Tartakovski B: Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum 1990; 20: 190200.
  • 22
    Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996; 80: S405.
  • 23
    Tugwell P, Bombardier C, Gent M, Bennett KJ, Bensen WG, Carette S, et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990; 335: 10515.
  • 24
    Emery P. Therapeutic approaches for early rheumatoid arthritis: How early? How aggressive? Br J Rheumatol 1995; 2 (Suppl 43): 8790.
  • 25
    Pasero G, Priolo F, Marubini E, Fantini F, Ferraccioli G, Magaro M, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996; 39: 100615.
  • 26
    Ferraccioli GF, Bambara LM, Ferraris M, Peppignano G, Cattaneo R, Porzio F, et al. Effects of cyclosporin on joint damage in rheumatoid arthritis. Clin Exp Rheumatol 1997; 15 (suppl 17): S839.
  • 27
    Alarcón GS, López-Méndez A, Walter J, Boerbooms AM, Russell AS, Furst DE, et al. Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis. J Rheumatol 1992; 19: 186873.
  • 28
    Kremer JM. Methotrexate and radiographic disease progression in patients with rheumatoid arthritis. J Rheumatol 1999; 26: 2413.